Screener
MiMedx Group MDXG SG&A
SG&A at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by MiMedx Group in its filing.
Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.
The source filing: MiMedx Group’s 10-Q, filed July 29, 2026.
- Filed
- Jul 29, 2026, 4:06 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001376339-26-000071
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Cost of sales | 19,981 | 18,681 | 37,348 | 35,239 |
| Gross profit | 44,381 | 79,924 | 86,005 | 151,571 |
| Operating expenses: | ||||
| Selling, general and administrative | 59,779 | 64,151 | 113,010 | 124,120 |
| Research and development | 2,777 | 3,303 | 6,917 | 6,632 |
| Amortization of intangible assets | 291 | 100 | 592 | 199 |
| Operating income | (18,466) | 12,370 | (34,514) | 20,620 |
| Other expense, net |
Item 1. Financial Statements
FAQ
- What is MiMedx Group's SG&A?
- MiMedx Group (MDXG) reported SG&A of $59.78M in Q2 2026.
- How has MiMedx Group's SG&A changed year-over-year?
- MiMedx Group's SG&A decreased by 6.8% year-over-year, from $64.15M to $59.78M.
- What is the long-term trend for MiMedx Group's SG&A?
- Over 4 years (2021 to 2025), MiMedx Group's SG&A has grown at a 7.6% compound annual growth rate (CAGR), from $198.36M to $266.19M.
- What does SG&A mean?
- Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.
Ask your AI about MiMedx Group's sg&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude